Public company info - Chaoju Eye Care Holdings Limited , 02219.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Chaoju Eye Care Holdings Limited, 02219.HK - Company Profile
Chairman Zhang Bozhou
Share Issued (share) 688,000,000
Par Currency Hong Kong Dollar
Par Value 2.5E-4
Industry Medical Equipment & Services
Corporate Profile Business Summary: The group is a leading ophthalmic medical service group in North China with a strong reputation nationwide. Performance for the year: The group’s revenue increased by 13.0% from RMB632.7 million in 2018 to RMB714.7 million in 2019, and further increased by 11.1% to RMB794.3 million in 2020. the group’s net profit also increased significantly from RMB29.2 million in 2018 to RMB70.8 million in 2019, and further increased by 70.2% to RMB120.5 million in 2020. Business Review According to the Frost & Sullivan Report, the group ranked first in Inner Mongolia, second in North China and fifth in China among private ophthalmic hospitals in terms of total revenue in 2020. China is a large and fast growing market for ophthalmic medical services. According to the Frost & Sullivan Report, the size of the ophthalmic medical services market in China increased from RMB73.0 billion in 2015 to RMB127.5 billion in 2019, representing a CAGR of 15.0%, and is expected to further grow to RMB223.1 billion in 2024; the size of the ophthalmic medical services market in North China increased from RMB13.2 billion in 2015 to RMB21.2 billion in 2019, representing a CAGR of 12.5%, and is expected to further grow to RMB33.7 billion in 2024; the size of the ophthalmic medical services market in Inner Mongolia increased from RMB1.1 billion in 2015 to RMB2.0 billion in 2019, representing a CAGR of 15.6%, and is expected to further grow to RMB3.3 billion in 2024. With an increasing population with high demands for ophthalmic medical services, it is expected that the ophthalmic medical services market in China has great potential for further growth. Leveraging the group’s experience in ophthalmic services and market leading position, the group believe The group is well-positioned to capture the growing opportunities and benefit from the rapid expansion of the ophthalmic services market in the PRC. The group were founded in 1988 in Baotou, Inner Mongolia, where Mr. Zhang Chaoju, a pioneer of modern ophthalmology in Inner Mongolia and an entrepreneur in the field of ophthalmic services in China, founded the predecessor of the group’s Company, a clinic providing ophthalmic services. The Zhang’s family is a medical family with a century’s heritage. Since the group’s inception, the group have adhered to the vision of “taking the group’s century’s heritage to bring light to the world and inspire hope” (百年朝聚，朝向光明，聚集希望) and provided patients with safe, reassuring and affordable ophthalmic medical experience with professional and effective equipment and technology as well as caring and considerate services. With a deep root in North China, the group have built a broad network of ophthalmic hospitals and optical centers spanning across five provinces or autonomous region in China, namely, Inner Mongolia, Zhejiang Province, Jiangsu Province, Shanxi Province and Hebei Province. As of the Latest Practicable Date, the group operated a network of 17 ophthalmic hospitals and 23 optical centers. In addition, as of the Latest Practicable Date, the group also operated two clinics as branches of the group’s hospitals, and one of the group’s optical centers also held a medical institution practicing certificate and was licensed to operate as a clinic providing certain out-patient services. The group generate revenue primarily from (i) consumer ophthalmic services and (ii) basic ophthalmic services. the group classify the group’s ophthalmic services primarily based on the type of disorders and diseases treated, type of treatments provided, eligibility for public health insurance program coverage and the generally accepted practice in the ophthalmic services industry. the group’s consumer ophthalmic services include treatments and prevention of various types of ophthalmic disorders, including refractive correction (including presbyopia correction), myopia control and provision of optical products and services, the costs for which are currently not covered by public health insurance programs. the group’s basic ophthalmic services include treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases, the cost of which are generally eligible to be covered by public health insurance programs. There is no overlap in the scope of the services provided and the diseases and corresponding treatments covered by the group’s basic ophthalmic services and consumer ophthalmic services. In light of upgraded social consumption in China over the recent years, the group plan to increase the group’s strategic focus on the group’s consumer ophthalmic services business and devote more efforts to pursue a continued rapid growth, while maintaining the fundamental strength of the group’s basic ophthalmic business. The group have a deep bench of ophthalmic experts with medical expertise and rich experience to treat a wide range of eye diseases and to provide various types of consumer ophthalmic services. the group focus on the quality of the group’s ophthalmic services and devote resources to allow the group’s ophthalmologists to provide ophthalmic medical services in a professional, dedicated and responsible manner. The group is also committed to recruiting and cultivating qualified professionals to form an ophthalmic medical team with outstanding professional and ethical standards and strong sense of responsibility. As of the Latest Practicable Date, the group’s medical professional team consisted of 261 registered physicians (including 67 multi-site practice physicians who were not the group’s full-time employees). Advanced technology and equipment is another key factor underpinning the group’s market leadership. the group’s patients are treated by ophthalmologists with latest technology and advanced equipment. According to the Frost & Sullivan Report, The group is the first-mover in Inner Mongolia to use micropulse laser technology to treat macular edema, to use minimally invasive vitreoretinal surgeries to treat vitreous and ocular fundus diseases, and to use artificial vitreous body implantations to protect the eye from atrophy. The group is a leader in Inner Mongolia to first introduce advanced medical equipment, such as OPTOS ultra-widefield fundus imaging system, vitreous cutter, optical coherence tomography for blood flow quantification, microfield detector and corneal confocal microscopy. the group believe that the group’s Baotou Hospital is the one-and-only ophthalmic hospital in Inner Mongolia with a preparation room to produce hospital-made traditional Chinese medicine capsules and eye drops. In particular, The group is one of the few medical service providers in China that are qualified to produce 0.01% atropine sulfate eye drops to be prescribed within the respective hospitals to control myopia among adolescents. the group believe that the group’s capabilities in hospital-made pharmaceuticals have helped improve the group’s brand awareness and customer loyalty, brought us competitive advantage in the area of myopia control and increased the group’s overall revenue. The group experienced a rapid growth during the Track Record Period. the group’s revenue increased by 13.0% from RMB632.7 million in 2018 to RMB714.7 million in 2019, and further increased by 11.1% to RMB794.3 million in 2020. the group’s net profit also increased significantly from RMB29.2 million in 2018 to RMB70.8 million in 2019, and further increased by 70.2% to RMB120.5 million in 2020. In 2018, 2019 and 2020, the group’s hospitals received 638,650 visits, 702,143 visits and 696,206 visits from the group’s patients, and the group’s optical centers received 73,935 visits, 79,903 visits and 91,660 visits from the group’s customers, respectively. Prospects: The group plan to implement the following strategies: • Continuing to reinforce the group’s leading position in Inner Mongolia and the surrounding regions, enhancing the group’s market position in Zhejiang Province, Jiangsu Province and other key regions, in the meantime developing the group’s featured ophthalmic hospitals. • Seizing opportunities in the consumer ophthalmic market to build a leading consumer ophthalmic brand in China. • Improving the utilization efficiency of the group’s regional resources and strengthening the group’s centralized management model with regional center hospitals as the core. • Continuously improving patient satisfaction and brand awareness. • Actively attracting and recruiting talents by further refining the group’s training programs, cultivating the group’s unique corporate culture and offering fair incentives to the group’s key employees.

Information from the financial statements of listed companies

 
88iv | Home |  Login
Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer
Copyright (C) 2024
Suntek Computer Systems Limited.
All rights reserved